Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in Adult Dermatomyositis
2021-001200-15Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dermatomyositis (DM) comparing Ravulizumab with Placebo (2 arms). Primary endpoint: Primary endpoint Part A. Started Jun 2021; status: completed.
02
Drugs
ravulizumab
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on 2021-001200-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001200-15.